77 results
Page 3 of 4
8-K
EX-99.2
pmmahk8alm
28 Jul 21
Alkermes plc Reports Second Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
vysbv8pteseics24z
1 Jun 21
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
7:09am
8-K
EX-99.2
dzh4uukd531x
28 Apr 21
Alkermes plc Reports First Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
22yws7r66lmsl
28 Apr 21
Alkermes plc Reports First Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
vp0rwbk6je5jesx6 vp7
25 Mar 21
Regulation FD Disclosure
12:00am
8-K
EX-99.2
nir1ayo
11 Feb 21
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
d0j1lk7zy
11 Feb 21
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
sxv 135282
11 Jan 21
Regulation FD Disclosure
7:00am
8-K
EX-99.1
ewxi ld0gqkc6u
6 Jan 21
Alkermes Announces Updates to Executive Leadership Team
4:24pm
8-K
EX-99.1
opxdu2pdi
10 Dec 20
Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
7:19am
8-K
EX-10.1
uzye3j979 cj0g
10 Dec 20
Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
7:19am
8-K
EX-99.1
swlsmw cg28
17 Nov 20
Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review
7:15am
8-K
EX-99.2
tdvjvfo wk
29 Oct 20
Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations
7:06am